CMV outcomes in CTL and control groups. (A) Cumulative incidence of first CMV reactivation in the subgroups used for comparative analysis (CTL group, n = 54; control group, n = 128). The day posttransplant of the landmark day (day 28) and the median day of infusion for the CTL group (day 45, range 29 to 115 days) are shown. The difference was not statistically significant (P = .10). (B) Peak CMV titer in CTL and control cohorts by quantitative PCR. Bars represent medians, boxes represent 25th to 75th percentiles, and whiskers represent 1.5 times the interquartile distance. Individual results outside these parameters are shown (●). (C) Number of days of treatment with intravenous anti-CMV therapy (ganciclovir, foscarnet, or both) for all patients in the CTL and control cohorts. Bars represent medians, boxes represent 25th to 75th percentiles, and whiskers represent 1.5 times the interquartile distance. Individual results outside these parameters are shown (●).